Breaking: Vertex makes $10B deal for commercial endocrinology biotech Crinetics
Vertex’s $10 billion buy of Crinetics sparks intense focus on biotech M&A.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics Pharmaceuticals, a commercial endocrinology biotech. Coverage highlights the deal as the largest in the sector to date, noting a near‑100 % after‑hours surge in Crinetics’ stock.
Bloomberg, The Wall Street Journal, STAT, Yahoo Finance and Endpoints News all reported the transaction. Analysts will monitor regulatory clearance and subsequent market moves as the deal progresses.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 43m ago.
Quick answers
What is the value of the Vertex‑Crinetics transaction?
The acquisition is valued at $10 billion, as reported by Bloomberg, The Wall Street Journal and other outlets.
Which company's shares surged after the announcement?
Crinetics’ stock rose nearly 100 % in after‑hours trading, according to Yahoo Finance.
How is the deal described in the coverage?
It is described as the biggest biotech M&A deal yet and part of a broader surge in biotech mergers, per STAT and Bloomberg.
Coverage (5)
- Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms STAT · 9h ago
- Vertex to Buy Crinetics for $10 Billion in Biggest Deal Yet Bloomberg.com · 9h ago
- CRNX Stock Soars Nearly 100% After-Hours On Vertex's $10B Acquisition Yahoo Finance · 9h ago
- Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion WSJ · 9h ago
- Breaking: Vertex makes $10B deal for commercial endocrinology biotech Crinetics Endpoints News · 9h ago
Topics
Related trends
Women with irregular periods should be checked for PMOS, NHS says
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Testosterone is being overprescribed to men
Recent reports indicate that testosterone therapy is frequently being prescribed to men without following established clinical guidelines.
Lilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’
Eli Lilly reports positive initial Phase 1 clinical data for its $2.3 billion acquisition of Ajax Therapeutics' myelofibrosis treatment.